UBS Wealth Management has partnered with American bioventure fund manager MPM Capital to launch cancer research impact investment scheme.
Commenting on the partnership, UBS Wealth Management president Jurg Zeltner said: "This is a significant step on the journey to make impact investing a mainstream asset class. To do that, we need to ensure that investment returns stack up, while also producing a social good."
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Swiss wealth management said that any investment opportunities arising out of this collaboration will likely be restricted to specific qualifying investors only and will not be available for general distribution.
UBS and MPM Capital will focus on cancer cure development by supporting academic research in this field.
Due to populations ageing in developed countries and an expanding middle class in emerging markets with better access to care, the market for cancer drugs is expected to grow faster than for any other disease.
Oncology is the largest and fastest growing therapeutic area in terms of drug development activity, representing approximately 23% of total research spend.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
